MoU Signing Ceremony between NIBM and NPRA

On 15 October 2025, the National Institutes of Biotechnology Malaysia (NIBM) and the National Pharmaceutical Regulatory Agency (NPRA) strengthened its strategic collaboration with the National Pharmaceutical Regulatory Agency (NPRA) through the signing of a Memorandum of Understanding (MoU) aimed at enhancing cooperation in the field of vaccine lot release.

The MoU was signed by YBhg. Prof. Datuk Wira Dr. Raha Abdul Rahim, FASc, Chief Executive Officer of NIBM, and YBrs. Dr. Azuana binti Ramli, Deputy Director-General of Health (Pharmaceutical Services).

 Under this MoU, NIBM will serve as a technical partner, providing support for testing activities and method development to ensure vaccine quality and safety, while NPRA will continue to function as the national regulatory authority responsible for vaccine evaluation and approval.

 In conjunction with the signing ceremony, Dr. Faisalina Ahmad Fisol delivered a presentation highlighting the facilities and laboratory capabilities at IPharm. The session was followed by a presentation by Chiong Yuh Lian from NPRA, who provided an overview of the implementation of the national lot release system and insights into Malaysia’s regulatory framework for vaccine quality assurance. The delegation also toured the Animal Research Facility (ARF) and the GMP Traditional Medicine Facility to gain a deeper understanding of NIBM’s research infrastructure.

This collaboration marks a significant step towards advancing research and development in vaccines , pharmaceutical, nutraceutical and biologics, fostering stronger institutional synergy in strengthening Malaysia’s healthcare ecosystem.